News stories about GenMark Diagnostics (NASDAQ:GNMK) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GenMark Diagnostics earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 46.8331487205241 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
GenMark Diagnostics (NASDAQ:GNMK) traded down $0.13 during trading on Friday, reaching $4.60. 357,944 shares of the company’s stock traded hands, compared to its average volume of 476,025. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.97 and a quick ratio of 2.77. The company has a market capitalization of $252.06, a P/E ratio of -3.74 and a beta of 0.65. GenMark Diagnostics has a 1-year low of $3.63 and a 1-year high of $13.67.
GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The business had revenue of $11.60 million during the quarter, compared to the consensus estimate of $14.56 million. GenMark Diagnostics had a negative return on equity of 100.33% and a negative net margin of 116.76%. The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.27) earnings per share. analysts predict that GenMark Diagnostics will post -1.18 earnings per share for the current year.
A number of analysts have recently issued reports on GNMK shares. Needham & Company LLC dropped their price objective on shares of GenMark Diagnostics from $15.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 3rd. Raymond James Financial reissued a “market perform” rating on shares of GenMark Diagnostics in a research note on Friday, November 3rd. Zacks Investment Research raised shares of GenMark Diagnostics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th. BidaskClub downgraded shares of GenMark Diagnostics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 2nd. Finally, Canaccord Genuity reissued a “buy” rating on shares of GenMark Diagnostics in a research note on Wednesday, September 27th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company. GenMark Diagnostics presently has an average rating of “Hold” and an average price target of $11.80.
In other news, Director Michael Kagnoff acquired 20,000 shares of the stock in a transaction dated Monday, November 6th. The stock was purchased at an average cost of $4.13 per share, with a total value of $82,600.00. Following the completion of the purchase, the director now owns 64,413 shares in the company, valued at approximately $266,025.69. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Hany Massarany sold 8,252 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $4.74, for a total transaction of $39,114.48. Following the transaction, the insider now directly owns 362,957 shares of the company’s stock, valued at $1,720,416.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,407 shares of company stock valued at $92,878. Insiders own 7.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “GenMark Diagnostics (GNMK) Earns Coverage Optimism Score of 0.09” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.thestockobserver.com/2018/01/13/genmark-diagnostics-gnmk-earns-coverage-optimism-score-of-0-09.html.
About GenMark Diagnostics
GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.